Edition:
United States

CEL-SCI Corp (CVM.A)

CVM.A on American Stock Exchange

0.08USD
24 Mar 2017
Change (% chg)

$-0.00 (-0.36%)
Prev Close
$0.08
Open
$0.09
Day's High
$0.09
Day's Low
$0.08
Volume
118,963
Avg. Vol
321,714
52-wk High
$0.60
52-wk Low
$0.06

CVM.A

Chart for CVM.A

About

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and... (more)
No analyst recommendations are available for CVM.A.

Overall

Beta: -1.13
Market Cap(Mil.): $18.08
Shares Outstanding(Mil.): 216.00
Dividend: --
Yield (%): --

Financials

  CVM.A Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -0.09 -- --
ROI: -100.52 -2.56 13.01
ROE: -257.92 5.14 14.16

BRIEF-Cel-Sci Corp scientist presents new findings for rheumatoid arthritis treatment vaccine

* Cel-Sci Corp - Cel-Sci scientist presents new findings for rheumatoid arthritis treatment vaccine

Feb 21 2017

BRIEF-CEL-SCI announces $1.0 million registered direct offering

* Intends to use net proceeds from offering for phase 3 clinical study Source text for Eikon: Further company coverage:

Feb 17 2017

BRIEF-CEL-SCI submits response to FDA in connection with partial clinical hold on phase 3 clinical trial

* CEL-SCI Corp - submitted response to FDA regarding partial clinical hold of CEL-SCI's phase 3 clinical trial of its investigational drug multikine

Nov 21 2016

BRIEF-CEL-SCI reports preclinical data showing leaps vaccine is successful in treating rheumatoid arthritis

* CEL-SCI reports preclinical data showing leaps vaccine is successful in treating rheumatoid arthritis

Nov 14 2016

BRIEF-Cel-Sci receives partial clinical hold letter from FDA

* Cel-Sci provides update on partial clinical hold on phase 3 clinical trial

Oct 21 2016

More From Around the Web

Competitors

Earnings vs. Estimates